A Phase 2, Open Label, Two Arm Trial To Evaluate The Efficacy Of PF-00299804 In Patients With Advanced NSCLC After Failure Of At Least One Prior Chemotherapy And Erlotinib.
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2014
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 02 Aug 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.